Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?
05 Sep 2023
Combination treatment with pembrolizumab and lenvatinib appears to be a better option for patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) with a platinum-free interval (PFI) of <6 months, suggests a recent study.
05 Sep 2023

Parkinson’s disease: More hours of good on-time with extended- vs immediate-release carbidopa-levodopa
05 Sep 2023
bởiNatalia Reoutova
IPX203, a new oral extended-release (ER) carbidopa-levodopa (CD-LD) combination, provides more hours of good on-time per day than immediate-release (IR) CD-LD, according to results of a phase III clinical trial in patients with Parkinson’s disease (PD).
05 Sep 2023







